Bio-Path (BPTH) Rises on Upbeat Updates From Blood Cancer Study
Bio-Path(BPTH) Zacks Investment Research·2024-04-19 15:16
Bio-Path Holdings, Inc. (BPTH) announced that it has completed the second dose cohort in the dose-escalation portion of an early-stage study evaluating its investigational candidate, BP1002, for the treatment of refractory/relapsed (R/R) acute myeloid leukemia (AML) patients, including venetoclax-resistant patients.The novel AML therapy, BP1002, is being developed by leveraging Bio-Path’s proprietary DNAbilize antisense RNAi nanoparticle technology. Per the company, BP1002 targets the Bcl-2 protein, which i ...